Abstract from Interim Report Q1-2010

FIRST QUARTER
• Net sales SKr 31.6, (26.6) million – increased with 19 %
• EBITDA SKr 3.0 (2.3) million
• Earnings before tax SKr 0.6 (1.3) million
• Net earnings SKr 23.3 (23.3) million*
• Earnings per share SKr 0.97 (1.16)
(* including deferred income tax of SKr 22.7 (22.0) million)

BUSINESS PROGRESS
• Sales growth 18th consecutive quarter, 19 % up compared to 2009
• Continuing strong growth in sales for Q-Sense, an increase of 33 % compared to 2009
• Strong sales increase and profitability improvements for Osstell
• Gross margin increased to 82 %
• EBITDA margin increased to 9.4 %
• Acquisition of Farfield
• Jan Wahlström appointed new CEO after Fredrik Lindgren
• Improved outlooks for 2010

CEO COMMENT
“The start of the year was positive with a sales growth of 19 %, the eighteenth consecutive quarter with sales growth. Q-Sense continued its positive development with a sales increase of 33 %. Osstell had a dramatic sales development with 97 % growth and generated strong earnings. Our gross margin improved, from an already high level, to 82 %. Furthermore, the strategically important acquisition of Farfield was executed during the quarter. We also managed to further strengthen our organisation by successful recruitment processes within sales and application development. This feels like a good point in time to hand over the leadership of Biolin Scientific to my successor”, says Fredrik Lindgren, resigning CEO for Biolin Scientific.